Journal of Thrombosis and Thrombolysis

, Volume 40, Issue 2, pp 211–217 | Cite as

Relation between ticagrelor response and levels of circulating reticulated platelets in patients with non-ST elevation acute coronary syndromes

  • Muthiah Vaduganathan
  • Noa Zemer-Wassercug
  • Eldad Rechavia
  • Hila Lerman-Shivek
  • Leor Perl
  • Dorit Leshem-Lev
  • Katia Orvin
  • Ran Kornowski
  • Eli I. Lev
Article

Abstract

Antiplatelet responses to clopidogrel and prasugrel are highly variable and subject to significant rates of high on-treatment platelet reactivity (HTPR) after percutaneous coronary intervention (PCI). The proportion of circulating young reticulated platelets (RPs) inversely correlates with responsiveness to both agents. We aimed to determine the relationship between RPs and on-treatment platelet reactivity in ticagrelor-treated patients. Patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) treated with PCI and ticagrelor were tested for platelet reactivity using the VerifyNow P2Y12 assay and multiplate aggregometry. RPs levels were determined using flow cytometry with thiazole orange staining. Tests were performed at 2–4 and 30 days post-PCI. Fifty three patients were included (mean age 62.6 ± 9.8 years, 18.9 % women, 35.8 % diabetes), of which 41 patients (77 %) completed follow-up. Variability in response to ticagrelor was very low according to both assays with no identified cases of HTPR at either time-point. In addition, there were no differences in platelet reactivity, as analyzed by the VerifyNow P2Y12 assay, or in the proportion of RPs between the two time points (p > 0.5). With the multiplate assay, platelet reactivity increased between the two time-points (8.6 ± 6.0 vs. 15.5 ± 11 AU*min; p = 0.0007). There was no significant correlation between RPs and platelet reactivity at both time-points and using both assays (p > 0.5). There were no cases of HTPR up to 30-days post-PCI in patients with NSTE-ACS treated with ticagrelor. In this cohort, no correlation between % RPs and platelet reactivity was observed. Attenuation of RP-induced platelet reactivity as a novel mechanism for ticagrelor’s benefit requires further investigation.

Keywords

Antiplatelet Percutaneous coronary intervention Platelet function Ticagrelor 

Notes

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Bonello L, Pansieri M, Mancini J, Bonello R, Maillard L, Barnay P, Rossi P, Ait-Mokhtar O, Jouve B, Collet F, Peyre JP, Wittenberg O, de Labriolle A, Camilleri E, Cheneau E, Cabassome E, Dignat-George F, Camoin-Jau L, Paganelli F (2011) High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 58(5):467–473. doi: 10.1016/j.jacc.2011.04.017 PubMedCrossRefGoogle Scholar
  2. 2.
    Michelson AD, Frelinger AL III, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD, Investigators T-T (2009) Pharmacodynamic assessment of platelet inhibition by prasugrel vs clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 30(14):1753–1763. doi: 10.1093/eurheartj/ehp159 PubMedCrossRefGoogle Scholar
  3. 3.
    Parguina AF, Grigorian-Shamajian L, Agra RM, Teijeira-Fernandez E, Rosa I, Alonso J, Vinuela-Roldan JE, Seoane A, Gonzalez-Juanatey JR, Garcia A (2010) Proteins involved in platelet signaling are differentially regulated in acute coronary syndrome: a proteomic study. PLoS One 5(10):e13404. doi: 10.1371/journal.pone.0013404 PubMedCrossRefGoogle Scholar
  4. 4.
    Robinson MS, Mackie IJ, Khair K, Liesner R, Goodall AH, Savidge GF, Machin SJ, Harrison P (1998) Flow cytometric analysis of reticulated platelets: evidence for a large proportion of non-specific labelling of dense granules by fluorescent dyes. Br J Haematol 100(2):351–357PubMedCrossRefGoogle Scholar
  5. 5.
    Lakkis N, Dokainish H, Abuzahra M, Tsyboulev V, Jorgensen J, De Leon AP, Saleem A (2004) Reticulated platelets in acute coronary syndrome: a marker of platelet activity. J Am Coll Cardiol 44(10):2091–2093. doi: 10.1016/j.jacc.2004.05.033 PubMedCrossRefGoogle Scholar
  6. 6.
    Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF, Kleiman NS (2007) Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5(3):490–496. doi: 10.1111/j.1538-7836.2007.02387.x PubMedCrossRefGoogle Scholar
  7. 7.
    Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, Granada JF, Dong JF, Kleiman NS, Lev EI (2008) Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 52(9):743–749. doi: 10.1016/j.jacc.2008.05.031 PubMedCrossRefGoogle Scholar
  8. 8.
    Perl L, Lerman-Shivek H, Rechavia E, Vaduganathan M, Leshem-Lev D, Zemer-Wassercug N, Dadush O, Codner P, Bental T, Battler A, Kornowski R, Lev EI (2014) Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 63(6):513–517. doi: 10.1016/j.jacc.2013.07.110 PubMedCrossRefGoogle Scholar
  9. 9.
    Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol 61(15):1601–1606. doi: 10.1016/j.jacc.2013.01.024 PubMedCrossRefGoogle Scholar
  10. 10.
    Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P (2012) Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60(3):193–199. doi: 10.1016/j.jacc.2012.03.050 PubMedCrossRefGoogle Scholar
  11. 11.
    Laine M, Frere C, Toesca R, Berbis J, Barnay P, Pansieri M, Michelet P, Bessereau J, Camilleri E, Ronsin O, Helal O, Paganelli F, Dignat-George F, Bonello L (2013) Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study. Thromb Haemost 111(2). doi: 10.1160/TH13-05-0384
  12. 12.
    Perl L, Zemer-Wassercug N, Rechavia E, Vaduganathan M, Orvin K, Weissler-Snir A, Lerman-Shivek H, Kornowski R, Lev EI (2014) Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction. J Thromb Thrombolysis. doi: 10.1007/s11239-014-1119-9 Google Scholar
  13. 13.
    Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Investigators P, Freij A, Thorsen M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045–1057. doi: 10.1056/NEJMoa0904327 PubMedCrossRefGoogle Scholar
  14. 14.
    Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V (2006) Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 28(5):315–322. doi: 10.1358/mf.2006.28.5.990205 PubMedCrossRefGoogle Scholar
  15. 15.
    Toth O, Calatzis A, Penz S, Losonczy H, Siess W (2006) Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 96(6):781–788PubMedGoogle Scholar
  16. 16.
    Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA, Working Group on High On-Treatment Platelet R (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56(12):919–933. doi: 10.1016/j.jacc.2010.04.047 CrossRefGoogle Scholar
  17. 17.
    Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ (2011) Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation 124(10):1132–1137. doi: 10.1161/CIRCULATIONAHA.111.029165 PubMedCrossRefGoogle Scholar
  18. 18.
    Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M, Group PHES (2013) Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J 34(3):220–228. doi: 10.1093/eurheartj/ehs149 CrossRefGoogle Scholar
  19. 19.
    Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G, Wallentin L, James SK, Group PS (2013) Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 128(10):1055–1065. doi: 10.1161/CIRCULATIONAHA.113.002589 PubMedCrossRefGoogle Scholar
  20. 20.
    Levin LA, Wallentin L, Bernfort L, Andersson D, Storey RF, Bergstrom G, Lamm CJ, Janzon M, Kaul P (2013) Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value Health 16(4):574–580. doi: 10.1016/j.jval.2013.01.013 PubMedCrossRefGoogle Scholar
  21. 21.
    Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey KW, Storey RF, Harrington RA, Wallentin L (2011) Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J 32(23):2933–2944. doi: 10.1093/eurheartj/ehr422 PubMedCrossRefGoogle Scholar
  22. 22.
    Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin L, Group PS (2012) Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 5(5):680–688. doi: 10.1161/CIRCOUTCOMES.111.964395 PubMedCrossRefGoogle Scholar
  23. 23.
    Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, Himmelmann A, Horrow J, Katus HA, Lassila R, Morais J, Nicolau JC, Steg PG, Storey RF, Wojdyla D, Wallentin L, PS Group (2014) The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J 35(23):1541–1550. doi: 10.1093/eurheartj/ehu075 PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Deharo P, Pankert M, Bonnet G, Quilici J, Bassez C, Morange P, Alessi MC, Bonnet JL, Cuisset T (2014) Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. Int J Cardiol. doi: 10.1016/j.ijcard.2014.07.228 Google Scholar
  25. 25.
    Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC, P Investigators (2010) Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749):1320–1328. doi: 10.1016/S0140-6736(10)61274-3 PubMedCrossRefGoogle Scholar
  26. 26.
    Serebruany VL (2010) Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor. Cardiology 117(3):231–233. doi: 10.1159/000322789 PubMedCrossRefGoogle Scholar
  27. 27.
    Bliden KP, Tantry US, Storey RF, Jeong YH, Gesheff M, Wei C, Gurbel PA (2011) The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 162(1):160–165. doi: 10.1016/j.ahj.2010.11.025 PubMedCrossRefGoogle Scholar
  28. 28.
    Palmerini T, Dangas G, Mehran R, Caixeta A, Genereux P, Fahy MP, Xu K, Cristea E, Lansky AJ, Stone GW (2011) Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial. Circ Cardiovasc Interv 4(6):577–584. doi: 10.1161/CIRCINTERVENTIONS.111.963884 PubMedCrossRefGoogle Scholar
  29. 29.
    Hirsh J, Glynn MF, Mustard JF (1968) The effect of platelet age on platelet adherence to collagen. J Clin Investig 47(3):466–473. doi: 10.1172/JCI105743 PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Karpatkin S (1969) Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Investig 48(6):1083–1087. doi: 10.1172/JCI106064 PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CP, Hillman RS (1992) The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 98(6):637–646PubMedGoogle Scholar
  32. 32.
    Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120(25):2577–2585. doi: 10.1161/CIRCULATIONAHA.109.912550 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Muthiah Vaduganathan
    • 1
  • Noa Zemer-Wassercug
    • 2
    • 3
  • Eldad Rechavia
    • 2
    • 3
  • Hila Lerman-Shivek
    • 2
    • 3
    • 4
  • Leor Perl
    • 2
    • 3
  • Dorit Leshem-Lev
    • 5
  • Katia Orvin
    • 2
    • 3
  • Ran Kornowski
    • 2
    • 3
  • Eli I. Lev
    • 2
    • 3
  1. 1.Department of Medicine, Massachusetts General HospitalHarvard Medical SchoolBostonUSA
  2. 2.Department of CardiologyRabin Medical CenterPetach TikvaIsrael
  3. 3.Sackler Faculty of MedicineTel-Aviv UniversityPetach TikvaIsrael
  4. 4.Clinical Pharmacy Department, School of PharmacyThe Hebrew University of JerusalemJerusalemIsrael
  5. 5.The Felsenstein Medical Research InstituteRabin Medical CenterPetach TikvaIsrael

Personalised recommendations